Financings in Brief: Genzyme
This article was originally published in The Gray Sheet
Executive Summary
Genzyme: Announces public offering of 2.5 mil. shares of its General Division common stock at $51.25 per share. Anticipated proceeds will go toward "general corporate purposes, including possible future acquisitions or reacquisitions of technology, product rights, and distribution rights," the firm states. CS First Boston, Cowen & Co., Lehman Brothers and PaineWebber are co-managing the offering...